The Geneva Gridlock: Why the Global Pandemic Treaty Has Run Into a Wall

Whenever the diplomacy of global health stalls in Geneva, nature conveniently provides a fresh argument for bureaucratic expansion. Speaking to negotiators gathered in Switzerland, World Health Organization Director-General Tedros Adhanom Ghebreyesus deployed the spectre of recent disease outbreaks to break a familiar deadlock. Pointing to an ongoing epidemic of the Ebola Bundibugyo virus in the Democratic Republic of the Congo and a hantavirus outbreak earlier in the year, his warning was straightforward: pathogen threats do not respect borders, and international rules must adapt accordingly.

Yet behind the urgent rhetoric lies a classic institutional dilemma. When member states enthusiastically adopted the framework Pandemic Agreement in May 2025, diplomats quietly bypassed its most contentious element simply to claim a diplomatic victory. They kicked the details of the Pathogen Access and Benefit-Sharing system down the road. Now that road has run out, and negotiators are forced to confront the complex mechanics they previously swept under the rug.

The conflict exposes a deep divide between wealthy nations and developing states. The proposed mechanism is supposed to regulate how sample data and dangerous biological material are shared across borders, while establishing mandatory rules for distributing vaccines, diagnostics, and therapeutics. Developing nations, remembering how they were sidelined during the COVID-19 pandemic while wealthier countries bought up supplies, hesitate to surrender pathogen samples without ironclad guarantees of access to the resulting medical treatments. Richer nations, home to the pharmaceutical firms that drive innovation, remain wary of binding distribution mandates.

Tedros highlighted that while private innovation produced COVID-19 vaccines in record time, unequal purchasing power left poorer populations waiting indefinitely. Hans Kluge, the WHO Regional Director for Europe who is currently on special leave to campaign for the organization’s top job, echoed this position via social media, arguing that prompt pathogen sharing must be paired with guaranteed access to affordable medicines to prevent past failures.

Whether moral pressure from WHO headquarters can bridge structural economic divides remains questionable. Asking sovereign nations to hand over scientific data while promising centralized equity sounds noble in a conference hall. Turning that concept into a working system without stifling innovation or creating endless administrative friction is quite another matter.

Written by Sandy van Dongen sandy.vandongen@alpineweekly.com